ESMO 2016 Congress

Präsenzveranstaltung

ESMO Congress is the leading oncology event in Europe. Nearly 2,900 abstracts were submitted. More than 19,000 participants from 130 countries worldwide are expected in Copenhagen.






Congress programme highlights:

- 80 late-breaking abstracts submitted, with top submissions in colorectal and gastrointestinal cancers, non-small-cell lung cancer, genito-urinary tumours and immunotherapy.
- Keynote lectures:
“The development of checkpoint inhibitors” by Jim Allison, Saturday, 8 October, 13:00
“The art of the possible: Bridging the gap between genomics and patient care?” by Emile Voest, Sunday, 9 October, 13:00
“The patient journey: Is cancer cure around the corner?”, by Jean-Charles Soria, Monday, 10 October, 13:00

- Onco-immunology: a fully dedicated track with more than 100 abstracts submitted, including hands-on educational sessions for practitioners, with a focus on patient selection and side-effect management.
- Record number of abstracts submitted under the Biomarkers topic, highlighting the importance of patient selection in treatment efficacy from the early phases of drug development to the bedside.
- Spotlight on resistance to therapy, the use of mouse models to help develop better targeted therapies and adapting clinical trials to tumour biology.
- The latest on BRCA testing in ovarian cancer and triple-negative breast cancer.
- Challenges and promises in the treatment of tumours of the central nervous system.
- How to provide patients with precision medicine in the clinic - interdisciplinary patient cases to translate theory into reality.
- A “Drugs you will be using in 2020” special symposium to share a vision of what to expect in the years ahead.
- Cancer prevention and screening including evidence-based prevention approaches.
- Public policy: sessions focusing on the most important public policy issues including the equitable delivery of anti-cancer drugs, the registration and use of Big Data and individual molecular profiles, and different approaches to qualify clinical benefit in oncology.